Page 251 - 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation

Summary, discussion and future perspectives
36. Hutchings M, Mous R, Clausen MR, et al. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study. Lancet. 2021 Sep 25;398(10306):1157-1169.
37. Tong C, Zhang Y, Liu Y, et al. Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/ relapsed B-cell lymphoma. Blood. 2020 Oct 1;136(14):1632-1644.
38. Cheson BD, Ansell S, Schwartz L, et al. Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. Blood. 2016 Nov 24;128(21):2489-2496.
39. PETRA consortium. Available from: https://petralymphoma.org/.
40. Mikhaeel NG, Smith D, Dunn JT, et al. Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL. Eur J Nucl Med Mol Imaging. 2016 Jul;43(7):1209-1219.
41. Mikhaeel NG, Cunningham D, Counsell N, et al. FDG-PET/CT after two cycles of R-CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome - final result of a UK National Cancer Research Institute prospective study. Br J Haematol. 2021 Feb;192(3):504-513.
42. Mamot C, Klingbiel D, Hitz F, et al. Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07). J Clin Oncol. 2015 Aug 10;33(23):2523-2529. Erratum in: J Clin Oncol. 2015 Sep 20;33(27):3074.
43. Carr R, Fanti S, Paez D, et al. IAEA Lymphoma Study Group. Prospective international cohort study demonstrates inability of interim PET to predict treatment failure in diffuse large B-cell lymphoma. J Nucl Med. 2014 Dec;55(12):1936-1944.
44. Zinzani PL, Gandolfi L, Broccoli A, et al. Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma. Cancer. 2011 Mar 1;117(5):1010-1018.
45. Mylam KJ, Kostakoglu L, Hutchings M, et al. (18)F-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic/US intergroup study. Leuk Lymphoma. 2015 Jul;56(7):2005- 2012.
46. Eertink JJ, Pfaehler EAG, Wiegers SE, et al. Quantitative radiomics features in diffuse large B-cell lymphoma: does segmentation method matter? J Nucl Med. 2022 Mar;63(3):389-395.
47. Eertink JJ, van de Brug T, Wiegers SE, et al. 18F-FDG PET baseline radiomics features improve the prediction of treatment outcome in diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging. 2022 Feb;49 (3):932-942.
48. Barrington SF, Zwezerijnen BGJC, de Vet HCW, et al. Automated Segmentation of Baseline Metabolic Total Tumor Burden in Diffuse Large B-Cell Lymphoma: Which Method Is Most Successful? A Study on Behalf of the PETRA Consortium. J Nucl Med. 2021 Mar;62(3):332-337.
49. Mikhaeel NG, Heymans MW, Eertink JJ, et al. A proposed new dynamic prognostic index for DLBCL: International Metabolic Prognostic Index (IMPI). Accepted at J Clin Oncol. 2022.
249
9